Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart f...

por Rossignol, Patrick, Williams, Bryan, Mayo, Martha R., Warren, Suzette, Arthur, Susan, Ackourey, Gail, White, William B., Agarwal, Rajiv
Publicado 2020

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

por Weir, Matthew R., Mayo, Martha R., Garza, Dahlia, Arthur, Susan A., Berman, Lance, Bushinsky, David, Wilson, Daniel J., Epstein, Murray
Publicado 2017

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

por Pitt, Bertram, Bakris, George L., Bushinsky, David A., Garza, Dahlia, Mayo, Martha R., Stasiv, Yuri, Christ‐Schmidt, Heidi, Berman, Lance, Weir, Matthew R.
Publicado 2015

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers

por Lesko, Lawrence J., Offman, Elliot, Brew, Christine Taylor, Garza, Dahlia, Benton, Wade, Mayo, Martha R., Romero, Alain, Du Mond, Charles, Weir, Matthew R.
Publicado 2017

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor block...

por Pitt, Bertram, Bakris, George L., Weir, Matthew R., Freeman, Mason W., Lainscak, Mitja, Mayo, Martha R., Garza, Dahlia, Zawadzki, Rezi, Berman, Lance, Bushinsky, David A.
Publicado 2018